A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients.
Rascol
O
O
Service de Pharmacologie Médicale et Clinique, INSERM U317, Faculté de Médecine, Toulouse, France.
Lees
A J
AJ
Senard
J M
JM
Pirtosek
Z
Z
Brefel
C
C
Montastruc
J L
JL
Fuell
D
D
D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007980:Levodopa / Q000627:therapeutic use; D009069:Movement Disorders / Q000188:drug therapy* / Q000503:physiopathology; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D017448:Receptors, Dopamine D2 / Q000819:agonists*
D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D007211:Indoles; D017448:Receptors, Dopamine D2; C046649:ropinirole; D007980:Levodopa